A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women

Carolyn J. Crandall, Joseph Larson, Jo Ann E. Manson, Jane A. Cauley, Andrea Z. LaCroix, Jean Wactawski-Wende, Mridul Datta, Maryam Sattari, John T. Schousboe, William D. Leslie, Kristine E Ensrud

Research output: Contribution to journalArticle

Abstract

The optimal approach to osteoporosis screening and treatment in postmenopausal women is unclear. We compared (i) the United States Preventive Services Task Force (USPSTF) and Osteoporosis Canada osteoporosis screening strategies; and (ii) the National Osteoporosis Foundation (NOF) and Canadian treatment strategies. We used data from the prospective Women's Health Initiative Observational Study and Clinical Trials of women aged 50 to 79 years at baseline (n = 117,707 followed for self-reported fractures; n = 8134 in bone mineral density [BMD] subset). We determined the yield of the screening and treatment strategies in identifying women who experienced major osteoporotic fractures (MOFs) during a 10-year follow-up. Among women aged 50 to 64 years, 23.1% of women were identified for BMD testing under the USPSTF strategy and 52.3% under the Canadian strategy. For women ≥65 years, 100% were identified for testing under the USPSTF and Canadian strategies, 35% to 74% were identified for treatment under NOF, and 16% to 37% were identified for treatment under CAROC (range among 5-year age subgroups). Among women who experienced MOF during follow-up, the USPSTF strategy identified 6.7% of women 50 to 54 years-old and 49.5% of women 60 to 64 years-old for BMD testing (versus 54.4% and 60.6% for the Canadian strategy, respectively). However, the specificity of the USPSTF strategy was higher than that of the Canadian strategy among women 50 to 64 years-old. Among women who experienced MOF during follow-up, sensitivity for identifying women as treatment candidates was lowest for both strategies in women aged 50 to 64 (NOF 10% to 38%; CAROC 1% to 15%) and maximal in 75-year-old to 79-year-old women (NOF 82.8%; 51.6% CAROC); specificity declined with advancing age and was lower with the NOF compared to the CAROC strategy. Among women aged 50 to 64 years, the screening and treatment strategies examined had low sensitivity for identifying those who subsequently experience MOF; sensitivity was higher among women ≥65 years than among younger women. New screening and treatment algorithms are needed.

Original languageEnglish (US)
JournalJournal of Bone and Mineral Research
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Osteoporosis
Advisory Committees
Osteoporotic Fractures
Therapeutics
Bone Density
Women's Health
Canada
Observational Studies

Keywords

  • BONE DENSITY
  • CANADIAN ASSOCIATION OF RADIOLOGISTS AND OSTEOPOROSIS CANADA
  • FRACTURE
  • FRAX
  • NATIONAL OSTEOPOROSIS FOUNDATION
  • OSTEOPOROSIS
  • UNITED STATES PREVENTIVE SERVICES TASK FORCE

Cite this

A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women. / Crandall, Carolyn J.; Larson, Joseph; Manson, Jo Ann E.; Cauley, Jane A.; LaCroix, Andrea Z.; Wactawski-Wende, Jean; Datta, Mridul; Sattari, Maryam; Schousboe, John T.; Leslie, William D.; Ensrud, Kristine E.

In: Journal of Bone and Mineral Research, 01.01.2019.

Research output: Contribution to journalArticle

Crandall, CJ, Larson, J, Manson, JAE, Cauley, JA, LaCroix, AZ, Wactawski-Wende, J, Datta, M, Sattari, M, Schousboe, JT, Leslie, WD & Ensrud, KE 2019, 'A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women' Journal of Bone and Mineral Research. https://doi.org/10.1002/jbmr.3636
Crandall, Carolyn J. ; Larson, Joseph ; Manson, Jo Ann E. ; Cauley, Jane A. ; LaCroix, Andrea Z. ; Wactawski-Wende, Jean ; Datta, Mridul ; Sattari, Maryam ; Schousboe, John T. ; Leslie, William D. ; Ensrud, Kristine E. / A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women. In: Journal of Bone and Mineral Research. 2019.
@article{ae268cd7e6f54389a440ce82cd150a54,
title = "A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women",
abstract = "The optimal approach to osteoporosis screening and treatment in postmenopausal women is unclear. We compared (i) the United States Preventive Services Task Force (USPSTF) and Osteoporosis Canada osteoporosis screening strategies; and (ii) the National Osteoporosis Foundation (NOF) and Canadian treatment strategies. We used data from the prospective Women's Health Initiative Observational Study and Clinical Trials of women aged 50 to 79 years at baseline (n = 117,707 followed for self-reported fractures; n = 8134 in bone mineral density [BMD] subset). We determined the yield of the screening and treatment strategies in identifying women who experienced major osteoporotic fractures (MOFs) during a 10-year follow-up. Among women aged 50 to 64 years, 23.1{\%} of women were identified for BMD testing under the USPSTF strategy and 52.3{\%} under the Canadian strategy. For women ≥65 years, 100{\%} were identified for testing under the USPSTF and Canadian strategies, 35{\%} to 74{\%} were identified for treatment under NOF, and 16{\%} to 37{\%} were identified for treatment under CAROC (range among 5-year age subgroups). Among women who experienced MOF during follow-up, the USPSTF strategy identified 6.7{\%} of women 50 to 54 years-old and 49.5{\%} of women 60 to 64 years-old for BMD testing (versus 54.4{\%} and 60.6{\%} for the Canadian strategy, respectively). However, the specificity of the USPSTF strategy was higher than that of the Canadian strategy among women 50 to 64 years-old. Among women who experienced MOF during follow-up, sensitivity for identifying women as treatment candidates was lowest for both strategies in women aged 50 to 64 (NOF 10{\%} to 38{\%}; CAROC 1{\%} to 15{\%}) and maximal in 75-year-old to 79-year-old women (NOF 82.8{\%}; 51.6{\%} CAROC); specificity declined with advancing age and was lower with the NOF compared to the CAROC strategy. Among women aged 50 to 64 years, the screening and treatment strategies examined had low sensitivity for identifying those who subsequently experience MOF; sensitivity was higher among women ≥65 years than among younger women. New screening and treatment algorithms are needed.",
keywords = "BONE DENSITY, CANADIAN ASSOCIATION OF RADIOLOGISTS AND OSTEOPOROSIS CANADA, FRACTURE, FRAX, NATIONAL OSTEOPOROSIS FOUNDATION, OSTEOPOROSIS, UNITED STATES PREVENTIVE SERVICES TASK FORCE",
author = "Crandall, {Carolyn J.} and Joseph Larson and Manson, {Jo Ann E.} and Cauley, {Jane A.} and LaCroix, {Andrea Z.} and Jean Wactawski-Wende and Mridul Datta and Maryam Sattari and Schousboe, {John T.} and Leslie, {William D.} and Ensrud, {Kristine E}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jbmr.3636",
language = "English (US)",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women

AU - Crandall, Carolyn J.

AU - Larson, Joseph

AU - Manson, Jo Ann E.

AU - Cauley, Jane A.

AU - LaCroix, Andrea Z.

AU - Wactawski-Wende, Jean

AU - Datta, Mridul

AU - Sattari, Maryam

AU - Schousboe, John T.

AU - Leslie, William D.

AU - Ensrud, Kristine E

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The optimal approach to osteoporosis screening and treatment in postmenopausal women is unclear. We compared (i) the United States Preventive Services Task Force (USPSTF) and Osteoporosis Canada osteoporosis screening strategies; and (ii) the National Osteoporosis Foundation (NOF) and Canadian treatment strategies. We used data from the prospective Women's Health Initiative Observational Study and Clinical Trials of women aged 50 to 79 years at baseline (n = 117,707 followed for self-reported fractures; n = 8134 in bone mineral density [BMD] subset). We determined the yield of the screening and treatment strategies in identifying women who experienced major osteoporotic fractures (MOFs) during a 10-year follow-up. Among women aged 50 to 64 years, 23.1% of women were identified for BMD testing under the USPSTF strategy and 52.3% under the Canadian strategy. For women ≥65 years, 100% were identified for testing under the USPSTF and Canadian strategies, 35% to 74% were identified for treatment under NOF, and 16% to 37% were identified for treatment under CAROC (range among 5-year age subgroups). Among women who experienced MOF during follow-up, the USPSTF strategy identified 6.7% of women 50 to 54 years-old and 49.5% of women 60 to 64 years-old for BMD testing (versus 54.4% and 60.6% for the Canadian strategy, respectively). However, the specificity of the USPSTF strategy was higher than that of the Canadian strategy among women 50 to 64 years-old. Among women who experienced MOF during follow-up, sensitivity for identifying women as treatment candidates was lowest for both strategies in women aged 50 to 64 (NOF 10% to 38%; CAROC 1% to 15%) and maximal in 75-year-old to 79-year-old women (NOF 82.8%; 51.6% CAROC); specificity declined with advancing age and was lower with the NOF compared to the CAROC strategy. Among women aged 50 to 64 years, the screening and treatment strategies examined had low sensitivity for identifying those who subsequently experience MOF; sensitivity was higher among women ≥65 years than among younger women. New screening and treatment algorithms are needed.

AB - The optimal approach to osteoporosis screening and treatment in postmenopausal women is unclear. We compared (i) the United States Preventive Services Task Force (USPSTF) and Osteoporosis Canada osteoporosis screening strategies; and (ii) the National Osteoporosis Foundation (NOF) and Canadian treatment strategies. We used data from the prospective Women's Health Initiative Observational Study and Clinical Trials of women aged 50 to 79 years at baseline (n = 117,707 followed for self-reported fractures; n = 8134 in bone mineral density [BMD] subset). We determined the yield of the screening and treatment strategies in identifying women who experienced major osteoporotic fractures (MOFs) during a 10-year follow-up. Among women aged 50 to 64 years, 23.1% of women were identified for BMD testing under the USPSTF strategy and 52.3% under the Canadian strategy. For women ≥65 years, 100% were identified for testing under the USPSTF and Canadian strategies, 35% to 74% were identified for treatment under NOF, and 16% to 37% were identified for treatment under CAROC (range among 5-year age subgroups). Among women who experienced MOF during follow-up, the USPSTF strategy identified 6.7% of women 50 to 54 years-old and 49.5% of women 60 to 64 years-old for BMD testing (versus 54.4% and 60.6% for the Canadian strategy, respectively). However, the specificity of the USPSTF strategy was higher than that of the Canadian strategy among women 50 to 64 years-old. Among women who experienced MOF during follow-up, sensitivity for identifying women as treatment candidates was lowest for both strategies in women aged 50 to 64 (NOF 10% to 38%; CAROC 1% to 15%) and maximal in 75-year-old to 79-year-old women (NOF 82.8%; 51.6% CAROC); specificity declined with advancing age and was lower with the NOF compared to the CAROC strategy. Among women aged 50 to 64 years, the screening and treatment strategies examined had low sensitivity for identifying those who subsequently experience MOF; sensitivity was higher among women ≥65 years than among younger women. New screening and treatment algorithms are needed.

KW - BONE DENSITY

KW - CANADIAN ASSOCIATION OF RADIOLOGISTS AND OSTEOPOROSIS CANADA

KW - FRACTURE

KW - FRAX

KW - NATIONAL OSTEOPOROSIS FOUNDATION

KW - OSTEOPOROSIS

KW - UNITED STATES PREVENTIVE SERVICES TASK FORCE

UR - http://www.scopus.com/inward/record.url?scp=85060152626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060152626&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3636

DO - 10.1002/jbmr.3636

M3 - Article

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

ER -